

## Etiologic Considerations of Nonspecific Pleuritis

Nam-Jae Kim, M.D., Suk-Chul Hong, M.D., Ju-Ock Kim, M.D.  
Ji-Won Suhr, M.D., Sun-Young Kim, M.D. and Heung-Kyu Ro, M.D.

Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea

Twenty-three patients with nonspecific pleuritis were studied to determine clinical outcome. After a mean follow-up period of 6 months (1 to 36 months), a diagnosis was reached in 17 patients, while 6 patients remained unknown.

The causes of the nonspecific pleuritis diagnosed on initial pleural biopsy were tuberculosis (11 patients, 48%), neoplasm (2 patients, 8.7%), parapneumonic effusion (1 patient), subphrenic abscess (1 patient), congestive heart failure (1 patient), and nephrotic syndrome (1 patient).

The diagnosis was made by therapeutic trials (tuberculosis: 11 patients, parapneumonic effusion: 1 patient, congestive heart failure: 1 patient), by repeat pleural biopsy in 1 hepatoma, by open thoractomy in 1 lung cancer, by exploratory laparotomy in 1 subphrenic abscess, and by kidney biopsy in 1 nephrotic syndrome.

The WBC counts (more than 2,000/mm<sup>3</sup>) and lymphocyte percentage (more than 60%) in the pleural fluid were significantly elevated in the patients with tuberculosis compared to those with malignant pleurisy, and other laboratory data were meaningless.

As a result of this investigation, we suggest that tuberculous pleurisy is the most common cause of nonspecific pleuritis in Korea and that therapeutic trial with anti-tuberculous medication for patients with high WBC count and lymphocyte percent in pleural fluid can help to locate the nonspecific pleuritis.

---

**Key Words:** Nonspecific pleuritis

### INTRODUCTION

Exudative pleural effusions are common manifestations, but sometimes its causes remain unknown. In Korea, the most common causes of exudative pleural effusion are tuberculosis in 59~64% and malignant neoplasms in 15~31%. However, 10~18% remain unknown<sup>1-3</sup>.

In western countries, the most common causes of exudative pleural effusion are malignant neoplasm in 35~68% and tuberculosis in 1~30% (mean 14%), where 12~24% remain unknown<sup>4-6,8,9</sup>.

The identification of the causes of exudate is necessary because treatment and prognosis are

determined according to etiologies, but some cases remained unknown despite extensive diagnostic studies (chest X-ray, biochemical assay of fluid, bacterial smear and culture, cytology, pleural biopsy and thoracoscopy). In these cases, repeated pleural biopsies and cytology increase the diagnostic yield in patients<sup>6-8</sup>) but add to the expense and morbidity of those patients.

The purpose of this investigation was to determine the causes of nonspecific pleuritis on initial pleural biopsies and to determine if individuals with nonspecific pleuritis could be distinguished from those with malignant or tuberculous pleural effusion by routine laboratory data.

### MATERIALS AND METHODS

#### 1. Subjects

All patients who had closed pleural biopsies performed from August 1985 to December 1989 at

---

Address reprint requests to: Sun-Young Kim, M.D.  
Department of Internal Medicine 640, Daesa Dong, Jung  
Gu, Dae Jeon 301-040, Korea

the Chungnam National University Hospital and who were diagnosed as having nonspecific pleuritis were included in this investigation.

Patients selected for the study met the following criteria: 1) exudative pleural effusion, 2) non-diagnostic biochemical, cultural, and cytologic studies of the fluid, and 3) nonspecific pleuritis diagnosed by closed needle biopsy of the pleura. Nonspecific pleuritis was characterized by the presence of one or several of the following: acute, subacute or chronic inflammation, fibrosis, or mesothelial cell hyperplasia.

There were 23 patients who met these criteria and were classified into 3 groups according to their ultimate diagnosis. Group I consisted of patients who were not diagnosed despite a variety of studies. Group II consisted of those who were ultimately diagnosed as having tuberculous pleurisy. Group III included those who were ultimately diagnosed as having malignant pleural effusion.

The controls were tuberculous pleurisy (15 cases) and malignant pleural effusion (11 cases, lung cancer) proven by initial pleural biopsy.

The ages of the patients in the nonspecific pleuritis group were  $46 \pm 13$  years, and for the control group it was  $43 \pm 20$  years in tuberculosis (15 cases) and  $55 \pm 12$  years in malignant pleural effusion (11 cases). The mean duration of follow-up in patients with nonspecific pleuritis, between the initial pleural biopsy and ultimate diagnosis, was 6(1-36) months (Table 1).

## 2. Methods

More than one biopsy was performed with a Cope needle. Three pieces of tissue were obtained and submitted for histologic study. Pleural fluid obtained at the time of the biopsy was routinely sent for cell count with differential, protein, glucose, bacterial and mycobacterial culture and cytologic examination. The chemotherapy criteria

included : 1) strongly positive intermediate strength tuberculin test, 2) pleural fluid lymphocyte greater than 50% and a protein level greater than 5.0 g/dl. But in this study, the tuberculin test did not apply.

A univariate analysis was done with Student's t-test and analysis of variance (ANOVA).

## RESULTS

### 1. Causes of Nonspecific Pleuritis

The final diagnosis explaining the pleural effusion and the diagnostic study or procedure that eventually established the cause are shown in Table 2. Tuberculosis was the most frequent cause, occurring in (47.8%) of the 23 patients. Other causes were malignancy in 2 (8.7%) patients, parapneumonic effusion, subphrenic abscess, congestive heart failure, and nephrotic syndrome in 1 patient, respectively. Six patients were placed in the indeterminate group (26.1%).

### 2. Diagnostic Procedures

Eleven cases were diagnosed as having tuberculous pleurisy empirically, i.e., they were cleared and had no recurrence after antituberculous chemotherapy.

Even though the initial clinical impression was malignancy in 2 patients with neoplastic disease, the diagnosis was not made early because the specimens from multiple biopsies were not diagnostic. Repeat pleural biopsies established that 1 patient had hepatoma which metastasized to the right pleural cavity 2 months later. Repeat pleural biopsies (5) were nondiagnostic in another patient who was subsequently diagnosed as lung cancer (adenocarcinoma) by open thoracotomy.

In parapneumonic effusion, sputum and pleural fluid culture were negative, but parenchymal infil-

**Table 1. The Distribution and Follow-up Duration of Subjects**

Subjects	Mean Age (yr.)	Sex (M/F)	Follow-up Duration (mo.)
Nonspecific pleuritis (n=23)	46 (20-64)	12/11	6 (1-36)
Controls			
Tbc. pleurisy (n=15)	43 (20-81)	10/ 5	13 (7-18)
Malignancy (n=11)	55 (25-74)	8/ 3	8 (3-19)

Controls : Tuberculous or malignant pleurise diagnosed on initial pleural biopse

Follow-up duration : Nonspecific pleuritis — between initial pleural biopsy and ultimate diagnosis ; Tbc. pleurisy and malignancy — between diagnosis and end point of treatment

**Table 2. Causes of Nonspecific Pleuritis (N=23)**

Final Diagnosis	Diagnostic Procedure or Study					Numbers (%)
	Clinical Trial	Pleural Biopsy	Open Thoracotomy	Explo-laparotomy	Kidney Biopsy	
Tuberculous	11					11 ( 48%)
Malignant						2 ( 8.7%)
Lung cancer			1			1
Hepatoma		1				1
Miscellaneous						4 ( 17%)
Parapneumonic effusion	1					1
Subphrenic abscess				1		1
Congestive heart failure	1					1
Nephrotic syndrome					1	1
Indeterminate						6 ( 26%)
Total	13	1	1	1	1	23 (100%)

**Table 3. Comparison of Parameters Between Nonspecific Pleuritis and Controls**

Diagnosis	WBC's (/mm <sup>3</sup> )	Lymph. (%)	Chol. (mg/dl)	Glucose (mg/dl)
Nonspecific pleuritis (n=23)	2,386 ± 643	67 ± 5	97 ± 29	95 ± 39
Controls				
Tbc. pleurisy (n=15)	1,961 ± 555*	75 ± 5*	117 ± 32	91 ± 17
Malignant pleurisy (n=11)	583 ± 531	50 ± 10	93 ± 22	75 ± 29

Lymph. (%) : percent of lymphocyte

Chol. : Cholesterol

\* : P-value &lt; 0.005 between tuberculous pleuritis and malignant effusion

tration and pleural effusion disappeared after a therapeutic trial of antibiotics. Subphrenic abscess was diagnosed by exploratory laparotomy. In 1 patient, congestive heart failure subsequently developed (neck vein engorgement, ventricular gallop sound, cardiomegaly and compatible echocardiographic findings to heart failure), so it was concluded that the initial effusion was directly or indirectly related to the heart failure. Then, the pleural effusion disappeared after digitalis therapy and the pleural fluid protein level had been 4.1 g/dl. One patient was recognized 3 months later as mesangiocapillary glomerulonephritis (MCGN) after closed pleural biopsy, and the pleural fluid protein level had been 3.5 g/dl.

The remaining 6 patients were ultimately classified as an indeterminate group and had received chemotherapy (INH, RFP, EMB, mean 4 months) for tuberculosis, but there was no response to chemotherapy.

### 3. Comparison of Parameters between Nonspecific Pleuritis and Controls

Table 3 shows the mean ± SD value of WBC, lymphocyte percentage, cholesterol and glucose in the pleural fluid of the patients with nonspecific pleuritis and controls (tuberculous and malignant pleurisy).

The pleural fluid WBC count of the patients with nonspecific pleuritis and controls (tuberculous and malignant pleurisy) were 2,389 mm<sup>3</sup>, 1,961 mm<sup>3</sup>, and 583/mm<sup>3</sup>, respectively. There were statistically significant differences in pleural fluid WBC counts between tuberculous and malignant pleurisy (p < 0.005).

The percentages of cells in the pleural fluid which were lymphocytes were 67%, 75% and 50%, respectively. There were statistically significant differences in the pleural fluid lymphocyte percentage between tuberculous and malignant pleurisy

**Table 4.** Comparison of Parameters Among the Nonspecific Pleuritis

Diagnosis	WBC's (/mm <sup>3</sup> )	Lymph. (%)	Chol. (mg/dl)	Glucose (mg/dl)
Tuberculous (n=11)	3,513 ± 974*	77 ± 12**	106 ± 44	86 ± 16
Malignant (n=2)	588 ± 95	50 ± 30	111 ± 12	140 ± 15
Indeterminate (n=6)	921 ± 370	55 ± 32	91 ± 24	99 ± 27

\* : P-value < 0.005 between tuberculous pleuritis and malignant effusion

\*\* : P-value < 0.05 between tuberculous pleuritis and malignant effusion

( $p < 0.005$ ). Cholesterol levels were 97 mg/dl, 117 mg/dl and 75 mg/dl, respectively, but there were no significant differences between these 3 groups. The lowest concentration of glucose was found in the malignant pleurisy group, but there was no statistically significant difference between these groups.

#### 4. Comparison of Parameters among the Nonspecific Pleuritis Group

The laboratory data of nonspecific pleuritis along its etiologies are shown in Table 4. The pleural fluid WBC count of the patients with ultimately diagnosed tuberculous pleurisy, ultimately diagnosed malignant pleurisy, and the indeterminate group were  $3,513 \pm 974/\text{mm}^3$ ,  $588 \pm 95/\text{mm}^3$  and  $921 \pm 370/\text{mm}^3$ , respectively. There were statistically significant differences between the ultimately diagnosed tuberculous and malignant pleurisy groups ( $p < 0.005$ ).

The pleural fluid lymphocyte percentage was significantly higher ( $p < 0.05$ ) in the patients with ultimately diagnosed tuberculous pleurisy (77%) than those with ultimately diagnosed malignant pleurisy (50%) and intermediate in the indeterminate group (55%), but the overlap was considerable. There were no statistically significant differences between these 3 groups in pleural cholesterol and glucose.

## DISCUSSION

Pleural effusion is an important and common clinical finding, but diagnosis of the causes of effusion is often difficult. The diagnosis of pleural effusion is most often established by chemistries of fluid, bacterial smear and culture, cytology for malignancy and closed pleural biopsy.

Diagnostic yield in patients with tuberculous pleurisy had been reported to 20~25% by pleural fluid culture, 60~80% by closed pleural biopsy, 76% by pleural biopsy culture and 95% by com-

bined pleural biopsy with pleural biopsy culture in the same patients<sup>10-12</sup>.

The yield of diagnosis of malignant pleurisy was 35~70% based on cytologic finding only and 40~70% on closed pleural biopsy findings only. When these 2 procedures are combined in the same patient, the yield approaches 90%<sup>8,13</sup>.

Reasons for the negative results of closed pleural biopsies in those patients who were ultimately diagnosed as having either malignant or tuberculous pleurisy are: 1) early lesion, 2) focal seeding with malignant nodule or granuloma or 3) absence of parietal pleural involvement<sup>34,35</sup>.

Salzer et al.<sup>18</sup>) reports that the causes of exudative pleural effusion in 271 patients were malignancy in 35%, tuberculosis in 20%, and parapneumonic effusion in 16%. Scerbo et al.<sup>6</sup>) notes that out of 163 patients, 40% were malignancy 30% were tuberculosis and 12% were parapneumonic effusion. Prakash et al.<sup>7</sup>) found that the causes of exudate in 414 patients were malignancy in 67.9% and tuberculosis in 1.4%, and Storey et al.<sup>4</sup>) found malignancy in 48% and tuberculosis in 1%.

In summary, the above literature reports that the most common cause of exudate is malignancy in 35~68%, then tuberculosis in 1~30%. Other causes were empyema, connective tissue disease and pulmonary infarction etc. In Korea, the causes of exudative pleural effusion were tuberculosis in 59~64% and variable malignancy in 15~31%<sup>1-3</sup>.

Storey et al.<sup>4,6,19</sup>) reported that 12~24% of patients with pleural effusion would remain without etiologic diagnosis despite usual diagnostic evaluations. Previous studies have shown that cases of idiopathic pleurisy which were diagnosed to nonspecific pleuritis on initial pleural biopsy, were malignancy in 25~40%. Others were connective tissue disease, pulmonary infarction, tuberculosis, systemic fungal infections, parapneumonic effusion, congestive heart failure, pancreatitis and hepatic disease. However, the indeterminate group

remained in the 12~35% range despite extensive studies<sup>14-16</sup>). In our investigation, tuberculosis was in 48% and malignancy in 8.7%; others were parapneumonic effusion, subphrenic abscess, congestive heart failure and nephrotic syndrome; 26% remained unknown.

Because the causes of pleural effusion often remain unsolved despite closed pleural biopsy, several biochemical parameters and tumor markers have been measured in pleural fluid to help in the differential diagnosis of various diseases. Liight et al. report that the WBC count and differential WBC count are useful diagnostically<sup>17,18</sup>), while Leuallen et al. conclude they are of no use<sup>5,19</sup>). Light et al. reported that the presence of predominantly polymorphonuclear leukocytes in pleural fluid indicates that the fluid is the result of acute pleural inflammation, hence raising the possibility of pneumonia with effusion, pulmonary infarction, and pancreatitis, while tuberculous and malignant effusions frequently had more than 50% lymphocytes in the pleural fluid. In this study, the WBC counts of patients with tuberculous pleural effusion were statistically significantly higher than those of patients with malignant pleural effusion in the controls ( $p < 0.005$ ). The study showed a statistically significant ( $p < 0.005$ ) higher value of WBC count in patients ultimately diagnosed as having tuberculous pleurisy than in those ultimately diagnosed as having malignant pleural effusion. Our results are compatible with those of Light et al.<sup>17</sup>) in tuberculous pleurisy but not in malignant pleural effusion.

It has been a of controversy the glucose concentration in the pleural fluid could aid the diagnosis of the causes of effusion. Calman et al.<sup>20</sup>) and Barber et al.<sup>21</sup>) report that a pleural fluid glucose concentration of less than 80 mg/dl suggests a diagnosis of tuberculous pleurisy. Also, Panadero et al.<sup>22</sup>) found that in cases with pleural glucose levels less than 60 mg/dl and pleural pH less than 7.30, there was a 90% probability of malignant effusion, while Glenert et al.<sup>23</sup>) and Light et al.<sup>24</sup>) have concluded they are of no use. Our results are in agreement with the latter 2 studies.

Elevated pleural fluid amylase level has been observed in pancreatitis and pancreatic tumor. Light et al.<sup>24</sup>) in a study of 10 cases of effusion in which amylase levels were more than 160 U/dl, report 8 cases were pancreatitis. By Hamm et al's study<sup>25</sup>), the mean cholesterol level in malignant effusions was 94 mg/dl, 76 mg/dl in inflammatory

effusion and 30 mg/dl in the transudates. The above study indicated that the pleural fluid cholesterol level was an aid in differentiating exudative, especially malignant, from transudative pleural effusions, but our results were not statistically significant.

In 1974, Cortes et al.<sup>30</sup>) proposed that measurement of the CEA level in pleural fluid suggested malignancy. Thereafter, several authors reported various arbitrary levels (CEA levels  $> 12$  ng/dl with a diagnostic sensitivity of 34%, Rittger et al.<sup>26</sup>);  $> 10$  ng/dl, 39%, Vladutiu et al.<sup>27</sup>); 20 ng/dl, 65%, Kim<sup>29</sup>) to separate malignant from benign effusions. But, Mckenna et al.<sup>28</sup>) found that the CEA level increased in adenocarcinoma only. Pleural fluid adenosine deaminase (ADA) levels in the patients with tuberculous pleurisy were significantly higher than those in the patients with nontuberculous pleurisy, and sensitivity and specificity at various cut-off levels (more than 30 IU/L, Prias et al.<sup>31</sup>); more than 40 IU/L, Lee et al.<sup>32</sup>); more than 50 IU/L, Sung et al.<sup>33</sup>) were over 90%. In this investigation some tests such as amylase, CEA and ADA in the pleural fluid were not performed. Our investigation was limited by the small population of patients studied and by nonperformance of thoracoscopy, pleural biopsy culture and tuberculin skin test.

From our work, we can report the following conclusions: 1) The causes of the nonspecific pleuritis diagnosed on initial pleural biopsy were tuberculosis (11 patients, 48%) and neoplasm (2 patients, 8.7%), while others were parapneumonic effusion, subphrenic abscess, congestive heart failure and nephrotic syndrome; 6 patients (26%) remained unknown. 2) WBC counts (more than 2,000/mm<sup>3</sup>) and lymphocyte percent (more than 60%) in pleural fluid were significantly elevated in the patients with tuberculous pleurisy compared to malignant pleurisy. 3) In view of the data obtained from our study, we suggest that therapeutic trial with antituberculous medication for patients with a high WBC count (2,000/mm<sup>3</sup>) and lymphocyte percent (more than 60%) in pleural fluid and who have been diagnosed as having nonspecific pleuritis on initial pleural biopsy can help to locate the etiologies.

## REFERENCES

1. Cho YC, Kim WH, Lee SM, Park BK, Doh SG: *Diagnostic significance in needle biopsy of pleura*. Korean J Int Med 23:361, 1980

2. Kim YJ, Lee EK, Jung JW, Park JR, Suh CY: *Clinical observation of exudative pleurisy and diagnostic significance in percutaneous needle biopsy of pleura. Korean J Int Med* 25:725, 1982
3. Kim JH, Ko YK, Kim WT, Jun JK, Jin SB, Song CS: *Clinical observation of exudative pleurisy. Korean J Int Med* 27:73, 1984
4. Storey DD, Dines DE, Coles DT: *Pleural effusion: A diagnostic dilemma. JAMA* 236:2183, 1976
5. Leuallen EC, Carr DT: *Pleural effusion: A statistical study of 436 patients. NEJM* 252:79, 1955
6. Scerbo J, Keltz H, Stone D: *A prospective study of closed pleural biopsies. JAMA* 218:377, 1971
7. Prakash UBS, Reiman HM: *Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion analysis of 414 cases. Mayo Clin Proc* 60:158, 1985
8. Salyer WR, Eggleston JC, Erozan YS: *Efficacy of pleural biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest* 67:536, 1975
9. Udaya BS, Prakash MD: *Comparison of needle biopsy with cytology analysis for the evaluation of pleural effusion; analysis of 414 cases. Mayo Clin Proc* 60:118, 1985
10. Von Hoff DD, Livolsi V: *Diagnostic reliability of needle biopsy of the parietal pleura. Am J Clin Path* 64:200, 1975
11. Berger HW, Mejia E: *Tuberculous pleurisy. Chest* 63:88, 1973
12. Levine H, Metzger W, Lacera D, Kay L: *Culture of pleural biopsy specimen. Arch Intern Med* 126: 269, 1970
13. Cope C: *New pleural biopsy needle-a preliminary study. JAMA* 167:1107, 1958
14. Gunnels JJ: *Perplexing pleural effusion. Chest* 74: 390, 1978
15. Ryan CJ, Rodgers RF, Unni KK, Hepper NGG: *The outcome of patients with pleural effusion of indeterminate cause at thoracotomy. Mayo Clinic Proc* 56:145, 1981
16. Leslie WK, Kinasewitz GT: *Clinical characteristics of patients with nonspecific pleuritis. Chest* 94: 603, 1988
17. Light RW, Erozan YS, Ball WC: *Cells in pleural fluid. Arch Intern Med* 132:854, 1973
18. Yam LT: *Diagnostic significance of lymphocytes in pleural effusions. Ann Intern Med* 66:972, 1967
19. Zinneman HH, Johnson JJ, Lyon RH: *Proteins and mucoproteins in pleural effusions. Am Rev Tuberc* 76:247, 1957
20. Calman WL: *Diagnostic value of the glucose content of serous pleural effusion. Br Med J* 1: 1239, 1951
21. Barber LM: *Glucose level in pleural fluid as a diagnostic aid. Chest* 31:680, 1957
22. Panadero FR, Mejias L: *Low glucose and PH levels in malignant pleural effusions. Am Rev Respir Dis* 139:163, 1989
23. Glenert J: *Sugar levels in pleural effusions of different etiologies. Acta Tuberc Scand* 42:222, 1962
24. Light RW, Ball WC: *Glucose and amylase levels in malignant pleural effusions. JAMA* 225:257, 1973
25. Hamm H, Broham U, Bohmer R, Missmahl HP: *cholesterol in pleural effusions. Chest* 92:298, 1987
26. Rittgers RA: *Carcinoembryonic antigen levels in benign and malignant pleural effusions. Ann Intern Med* 88:631, 1978
27. Uladuti AO, Brason FW, Adler RH: *Differential diagnosis of pleural effusions. Chest* 79:297, 1981
28. Mckenna JM, Chandrasekhar AJ, Henkin RE: *Diagnostic value level in various pleural effusions. Chest* 78:587, 1981
29. KIM SY: *The clinical significance of carcinoembryonic antigen level in various pleural effusions, Chungnam Medical Journal.* 10:1, 1983
30. Cortes EP, Chawla S, Reddy P, Chu TM: *Carcinoembryonic antigen in extracellular fluid: benign or malignant? Cancer Res* 23:596, 1975
31. Piras MA, Gakis C, Budroni M, Andreoni G: *Adenosin deaminase activity in pleural effusions. Br Med J* 4:1751, 1978
32. Lee CH, Kim SK, Ahn CM, Jang SH, Sohn HY, Kim KH: *Clinical significance of adenosine deaminase activity in various pleural effusion. Korean J Int Med* 31:781, 1986
33. Sung NU, Shin KC, Lee KW: *A study on adenosine deaminase activity in patients with pleural effusion of various causes. Korean J Int Med* 33:240, 1987
34. Chernow B, Sahn SA: *Carcinomatous involvement of the pleura. Am J Med* 63:695, 1977
35. Meyer PC: *Metastatic carcinoma of the pleura. Thorax* 23:437, 1966